Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 400-404

  Negredo, Eugenia ^a   Puigdomènech, Isabel ^a   Marfil, Silvia ^a   Puig, Jordi ^a   Pérez Álvarez, Núria ^a,b   Ruiz, Lidia ^a   Rey joly, Celestino ^a   Clotet, Bonaventura ^a   Blanco, Julià ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

Atorvastatin; Lipid; Membrane; Metabolism; PBMC; Replication

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CD4 LYMPHOCYTE COUNT; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PILOT PROJECTS; VIRUS REPLICATION;

EID: 38349126712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm470     Document Type: Article

References (23)

1. Izquierdo-Useros N, Blanco J, Erkizio I et al. Maturation of blood derived dendritic cells enhances HIV-1 capture and transmission J Virol 2007; 81: 7559-70.
2. Del Real G; Jimenez-Baranda S, Lacalle RA et al. Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002; 196: 293-301.
3. Jolly C, Sattentau QJ. Human Immunodefictency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J Virol 2005; 79: 12088-94.
4. van 't Wout AB, Swain JV, Schindler M et al. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J Virol 2005; 79: 10053-8.
5. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-82.
6. Corsisi A, Bellosta S, Baetta R et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
7. del Real G, Jimenez-Baranda S, Mira E et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200 541-7.
8. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78: 12062-5.
9. Nabatov AA, Pollakis G, Linnemann T et al. Statins disrupt CCR5 and RANTES expression levels in CD4 T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS ONE 2007; 2: 9470.
10. Sklar PA, Masur H, Grubb JR et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on anti-retroviral therapy. AIDS 2005; 19: 1109-11.
11. Waters L, Stebbing J, Jones R et al. The effect of statins on HIV rebound and blips. J Acquit Immune Defic Syndr 2005; 39: 637-8.
12. Negredo E, Clotet B, Puig J et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS 2006, 20: 619-21.
13. Barretina J, Blanco J, Bonjoch A et al. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18: 1673-82.
14. Eggesbo JB, Hagve TA, Borsum K et al. Lipid composition of mononuclear cell membranes and serum from persons with high or low levels of serum HDL cholesterol. Scand J Clin Lab Invest 1996; 56: 199-210.
15. Martinez M, Vaya A, Marti R et al. Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia. Haemositasis 1996; 26 Suppl 4: 171-6.
16. Koter M, Broncel M, Chojnowska-Jezierska J et al. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur J Clin Pharmacol 2002; 58: 501-6.
17. Parker RA, Clark RW, Sit SY et al. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res 1990; 31: 1271-82.
18. Owens D, Collins P, Johnson A et al. Cellular cholesterol metabolism in mitogen-stimulated lymphocytes-requirement for de novo synthesis. Biochim, Biophys Acta 1990; 1051: 138-43.
19. Kurakata S, Kada M, Shimoda Y et al. Effects of different inhibitors of 3-hydroxy3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996; 34: 51-61.
20. Wibaut-Berlaimont V, Randi AM, Mandryko V et al. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost 2005; 3: 677-85.
21. Dunn SE, Youssef S, Goldstein MJ et al. Isoprenoids determine Th1/ Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203: 401-12.
22. Cherfan P, Tompa A, Wikby A et al. Effects of simvastatirr on human T cells in vivo. Atherosclerosis 2007; 193: 186-92
23. Arora M, Chen L, Paglia M et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci USA 2006; 103: 7777-82.